New Collaborative Study Uses Pangea Biomed’s Platform to Create World’s First Sequencing-Free, Transcriptomics-Based Drug Response Predicting System; Novel Approach to Precision Cancer Care Combines AI Techniques and Digital Pathology

On June 13, 2023, Pangea Biomed, the company that created ENLIGHT, which it  believes to be the world’s most advanced multi-cancer response predictor, announced the publication of research demonstrating the first-ever combined digital pathology and expression-based approach for predicting patient response to cancer treatment. This novel research, named ENLIGHT-DeepPT, applies Pangea’s original ENLIGHT platform to the gene expressions predicted by the new DeepPT framework, demonstrating for the first time a genetic interactions (GI)-based approach for predicting patient response to treatment. Published in the non-peer-reviewed bioRxiv, the study was led by Eytan Ruppin, MD, PhD, Chief of the Cancer Data Science Lab with Kenneth Aldape, MD, Chief of Pathology at the National Cancer Institute’s Center for Cancer Research (NCI/CCR), part of the National Institutes of Health, in collaboration with Pangea Biomed, as well as Danh Tai Hoang,PhD, and Eric Stone, PhD, at the Australian National University. The study is titled “Synthetic Lethality-Based Prediction of Cancer Treatment Response from Histopathology Images.”